EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study

Jiangwei Sun, Karl Mårild, David Bergman, Fahim Ebrahimi, SWIBREG Study Group, Jonas Halfvarson, Ola Olén, Jonas F Ludvigsson

Clinical Gastroenterology and Hepatology · 2026-05 · 24 (5) · 1384-1392

DOI: 10.1016/j.cgh.2025.10.030 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Jiangwei Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: jiangwei.sun@ki.se. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Svenska Sällskapet för Medicinsk Forskning, European Crohn's and Colitis Organisation, Ruth och Richard Julins Stiftelse.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Inflammatory bowel disease (IBD) is associated with increased mortality risk. However, whether this risk is influenced by histologic and clinical activity remains uncertain. METHODS: A nationwide cohort study in Sweden. We compared mortality rates linked to histologic inflammation in 63,358 patients diagnosed with IBD 1969-2017 and to clinical activity in 102,352 patients diagnosed 1969-2020. The adjusted hazard ratio (aHR) of mortality within 2 years after index date (ie, date of histologic/clinical activity) was estimated using cause-specific hazard model, with 95% confidence intervals (CIs). RESULTS: A higher 2-year all-cause mortality was observed after histologic inflammation than after histologic remission (mortality rate: 121.0 vs 64.8 per 10,000 person-years; aHR, 1.45; 95% CI, 1.30-1.61). This excess risk was observed in all IBD subtypes: Crohn's disease (aHR, 1.42; 95% CI, 1.16-1.73), ulcerative colitis (aHR, 1.44; 95% CI, 1.26-1.65), and IBD unclassified (aHR, 1.56; 95% CI, 1.01-2.41). Clinically active IBD was also associated with an increased 2-year all-cause mortality compared to quiescent IBD (mortality rate: 352.6 vs 106.3 per 10,000 person-years; aHR, 3.35; 95% CI, 3.21-3.49). Even in patients with clinically quiescent IBD, histologic inflammation was associated with an increased 2-year all-cause mortality (aHR, 1.42; 95% CI, 1.08-1.87). CONCLUSIONS: Both histologic inflammation and clinical activity of IBD were associated with increased all-cause mortality, suggesting that improved disease control may reduce mortality risk in IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesHumansSwedenMaleFemaleAdultMiddle AgedCohort StudiesYoung AdultAdolescentAgedRemission InductionCrohn Disease

Stichwörter der Autor:innen

Clinical activityCohortHistologic inflammationInflammatory bowel diseaseMortality

Autor:innen und Institutionen

  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. Electronic address: jiangwei.sun@ki.se.
  • Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg, Sweden; Department of Pediatrics, Queen Silvia Children's Hospital, Gothenburg, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology and Hepatology, University Digestive Health Care Center Basel - Clarunis, Basel, Switzerland.
  • Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
  • Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Sachs' Children and Youth Hospital, Stockholm South General Hospital, Stockholm, Sweden.

Förderung

  • Svenska Sällskapet för Medicinsk Forskning
  • European Crohn's and Colitis Organisation
  • Ruth och Richard Julins Stiftelse
  • Karolinska Institutet

Zitieren

APA

Sun, J., Mårild, K., Bergman, D., Ebrahimi, F., SWIBREG Study Group, Halfvarson, J., Olén, O., & Ludvigsson, J. F. (2026). Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. Clinical Gastroenterology and Hepatology, 24(5), 1384-1392. https://doi.org/10.1016/j.cgh.2025.10.030

Vancouver

Sun J, Mårild K, Bergman D, Ebrahimi F, SWIBREG Study Group, Halfvarson J, et al. Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. Clinical Gastroenterology and Hepatology. 2026;24(5):1384-1392. doi:10.1016/j.cgh.2025.10.030

BibTeX
@article{Sun2026,
  author = {Sun, Jiangwei and Mårild, Karl and Bergman, David and Ebrahimi, Fahim and SWIBREG Study Group, SWIBREG Study Group and Halfvarson, Jonas and Olén, Ola and Ludvigsson, Jonas F},
  title = {Histologic Remission and Mortality in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  volume = {24},
  number = {5},
  pages = {1384--1392},
  doi = {10.1016/j.cgh.2025.10.030}
}
Kostenlos starten →